Group 1 - The core viewpoint of the article is that the Hong Kong innovative drug sector has seen a significant recovery in liquidity since the beginning of 2026, leading to a positive market outlook [1] - The report highlights that the upcoming JPM Healthcare Conference is expected to further boost the Chinese biopharmaceutical (BD) transactions, which have already shown substantial growth compared to the same period last year [1] - Huatai Securities anticipates that the liquidity recovery at the start of the year will trigger a clear beta rally in innovative drugs, with expectations of breaking previous highs [1] Group 2 - The external demand-driven Contract Research Organization (CXO) sector is expected to continue exceeding performance expectations due to the demand for new molecules, potentially resonating with the innovative drug sector [1]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [5] Core Insights - Domestic innovative drugs are expected to lead the tumor immunotherapy 2.0 era, with bispecific antibodies becoming a global focus and business development (BD) transaction volumes reaching new highs. The global value of Chinese innovative drugs is being rapidly uncovered [3][6] - A significant collaboration was established between Rongchang Biopharma and AbbVie, involving the PD-1/VEGF bispecific antibody (RC148), which includes a $650 million upfront payment and potential milestone payments of up to $4.95 billion, along with double-digit royalties on net sales outside Greater China. This partnership accelerates the internationalization of RC148 and highlights the potential of the tumor pipeline [6] - The report emphasizes the increasing interest from multinational pharmaceutical companies in domestic bispecific antibody drugs, indicating that these innovative drugs will be a key growth engine in the tumor immunotherapy 2.0 era [6] Summary by Sections Industry Overview - The pharmaceutical and biotechnology industry is positioned for growth, particularly in the area of innovative drugs and tumor immunotherapy [5] Investment Recommendations and Targets - Key investment targets include Rongchang Biopharma (688331), 3SBio (01530), 3SBio Guojian (688336), Innovent Biologics (01801), CanSino Biologics (09926), Kintor Pharmaceutical (06990), and Eucure Biopharma (09606), all of which are not rated yet [3] Recent Developments - The collaboration between Rongchang Biopharma and AbbVie is a pivotal event, marking a significant step in the global commercialization of innovative drugs [6]

Core Viewpoint - The innovative drug sector has shown a strong recovery since the beginning of 2026, with increased attention and investment opportunities due to a surge in small nucleic acid listings and ongoing international business development transactions, reflecting global recognition of Chinese innovative drugs [1][7]. Group 1: Investment Timing and Strategy - The Longcheng Pharmaceutical Industry Selected Fund was established in October 2024, shortly after a strong market rebound, which initially affected performance due to market volatility [1][4]. - The fund manager identified the innovative drug sector as having long-term growth potential and value realization opportunities, especially following significant policy shifts that improved the industry environment [1][4]. Group 2: Factors for Sector Layout and Stock Selection - Key considerations for sector layout include the growth potential and development space of the industry, as well as identifying listed companies that can benefit from industry opportunities [1][4]. - The stock selection process involves a "three-cycle framework" focusing on supply-demand cycles, company fundamentals, and capital market cycles to determine stock positions [1][4]. Group 3: Investment Strategy - The investment strategy employs a "three-cycle resonance" approach, seeking companies that align with industry, company growth, and capital market cycles [2][5]. - The focus is on capturing profits from rapid company earnings growth and recognizing valuation expansion potential in companies with "explosive product" logic [2][5]. Group 4: Market Outlook for 2026 - The innovative drug sector is expected to continue performing well in 2026, particularly in the first half, although the difficulty of market timing and stock selection will increase compared to 2025 [3][6]. - The fund manager remains highly focused on innovative drugs, anticipating that certain stocks will gradually realize returns as they reach target market values over the next 1-2 years [3][6].

Group 1: Grid Trading Strategy Overview - The essence of "grid trading" is a high buy low sell strategy, which does not predict market trends but utilizes natural price fluctuations within a certain range to generate profits, suitable for frequently fluctuating markets [4][13] - Characteristics of suitable grid trading targets include: selecting on-market targets, stable long-term trends, low trading costs, good liquidity, and high volatility. Equity ETFs are considered relatively suitable for grid trading [4][13] Group 2: ETF Grid Strategy Target Analysis - **Hang Seng Medicine ETF (159892.SZ)**: Benefiting from the Federal Reserve's interest rate cut cycle, which improves the financing environment for innovative drugs. China's innovative drugs are accelerating their globalization, becoming a core driver for commercialization. As of January 4, 2026, China's new drug pipeline accounts for about 30% of the global total, ranking second worldwide. In 2025, 76 innovative drugs were approved for marketing in China, with domestic innovative drugs accounting for 80.85% of chemical drugs and 91.30% of biological products [4][14] - **Brokerage ETF (159842.SZ)**: High market activity catalyzes the release of brokerage performance, with capital market reforms opening up long-term growth space for leading brokerages. The Shanghai Composite Index rose from a low of 3040 points to break through 4000 points, with an annual increase of 18.41%. The total A-share trading volume reached 420.21 trillion yuan, a year-on-year increase of 62.64% [5][17] - **New Economy ETF (159822.SZ)**: A one-stop layout for high-quality new economy leading enterprises in China, capturing the key to economic transformation. The ETF indirectly tracks the S&P China New Economy Industry Index, holding leading companies in artificial intelligence, internet, biotechnology, and innovative drugs, which are high-growth sectors [6][19] - **Coal ETF (515220.SH)**: Benefiting from the "anti-involution" policy and dividend investment logic. The central economic work conference in December 2025 identified "deepening the rectification of 'involutionary' competition" as a key task for 2026, which is expected to control new capacity and improve the coal industry's supply-demand fundamentals. As of January 13, 2026, the coal sector's dividend yield reached 5.52%, significantly higher than the market average and the yield on ten-year government bonds [7][22]

Group 1 - The core viewpoint is that the integration of AI in healthcare and pharmaceuticals is gaining momentum, with significant stock price increases in related companies such as Meinian Health and Zhaoyan New Drug [1] - The Medical Equipment ETF (159873) has seen continuous capital inflow over the past four days, totaling 26.5 million yuan, reaching new highs in both scale and shares since its inception [2] - The Medical Equipment ETF has a high concentration in brain-computer interface technology, accounting for over 17%, with nearly 80% of its components from the Sci-Tech Innovation Board and the Growth Enterprise Market, indicating strong technological attributes [2] Group 2 - The Innovative Drug ETF Tianhong (517380) has experienced net inflows for six consecutive days, with a total of 254 million yuan in the last five days, reflecting strong investor interest [3] - The Innovative Drug ETF spans the Shanghai, Hong Kong, and Shenzhen markets, covering the entire industry chain from preclinical research to commercialization, which helps mitigate investment uncertainties [3] - OpenAI's launch of ChatGPTHealth marks the beginning of an AI-driven healthcare era, enhancing privacy through data isolation and involving over 260 doctors from 60 countries in model optimization [3]

Core Insights - The Chinese biotechnology industry is experiencing significant growth in research and development (R&D) driven by policy incentives, leading to a substantial increase in the approval of innovative drugs and medical devices by mid-2025 [1] - The application of artificial intelligence (AI) is accelerating the digitalization and intelligence of pharmaceutical R&D, while the Hong Kong Stock Exchange's technology enterprise channel facilitates the listing of biotech companies [1] - China's pharmaceutical companies are shifting from relying on technology imports to focusing on independent innovation, with a notable increase in globalization [1] Industry Developments - As of December 31, 2024, the number of active innovative drug R&D projects in China has reached 3,575, surpassing the United States and making China the global leader [1] - The License-out transaction model has become mainstream among Chinese pharmaceutical companies, further promoting the internationalization of innovative drugs [1] - The CXO (Contract Research Organization) industry is experiencing robust growth driven by the demand for innovative drug R&D and production [1] Investment Opportunities - The Hang Seng Biotechnology Index focuses on innovative drugs, presenting three key advantages: concentration of leading companies, scarcity of futures liquidity, and high elasticity & Sharpe ratio [1] - Investors looking to conveniently participate in the core leaders of innovative drugs can consider the Hang Seng Biotechnology ETF (520933) for streamlined investment [1]

Group 1 - The pharmaceutical sector is leading the market with significant gains, driven by multiple overseas innovative drug collaborations and catalysts [1] - Notable partnerships include Rongchang Biopharma's licensing agreement with AbbVie, which involves an upfront payment of $650 million and potential milestone payments of $4.95 billion, along with double-digit sales royalties [1] - WuXi AppTec has projected a revenue increase of 15.84% for 2025, with adjusted net profit expected to rise by 41.33%, exceeding market expectations [1] Group 2 - AI in healthcare is gaining momentum, with OpenAI integrating health dialogue features into ChatGPT, allowing users to share medical records and connect with various health applications [2] - Tempus AI reported a 111% year-over-year increase in diagnostic revenue, reaching $955 million, highlighting the rapid growth of AI in the medical field [2] - The pharmaceutical sector's global competitiveness is strengthening, with ongoing commercialization and profitability, particularly in innovative drug companies and CXO sectors [2]

Core Insights - The PD-1/VEGF dual antibody sector is experiencing a divergence, with Yiming Biotech facing setbacks due to the return of its PD-L1/VEGF dual antibody by partner Axion, while Rongchang Biotech secured a significant licensing deal worth $5.6 billion with AbbVie, highlighting the increasing differentiation within the dual antibody space and outlining the core investment theme for 2026: certainty [1][2] Group 1: Investment Trends - The investment landscape in the pharmaceutical sector is shifting from a focus on broad-based licensing deals to a preference for certainty in value, emphasizing three core anchors: expectation certainty, product certainty, and performance certainty [2][6] - The previous trend of "BD is king" in 2025 led to a surge in licensing deals, but the market is now recalibrating its valuation logic, moving away from blind enthusiasm towards a more rational assessment of the feasibility of these deals [1][2] Group 2: Expectation Certainty - Expectation certainty involves a rational evaluation of the feasibility of BD transactions rather than blind pursuit of total deal amounts, as the probability of new drugs progressing from early clinical stages to market approval is only 7.9% [3][4] - The competitive landscape in the PD-1/VEGF dual antibody sector shows that not all players can achieve their expected value due to overlapping targets and indications, mirroring past trends in the PD-1 monoclonal antibody market [3][4] Group 3: Product Certainty - Product certainty focuses on the potential for substantial sales post-launch, with products that have clear growth logic expected to command higher valuations [5][6] - WanTai Biotech's nine-valent HPV vaccine, priced at 499 yuan per dose (40% of imported vaccines), is positioned for significant market penetration, while Innovent Biologics' Ma Shidu peptide faces challenges due to increased competition and pricing pressures, leading to diminished commercial value [5][6] Group 4: Performance Certainty - Performance certainty seeks companies and sectors with clear growth or recovery expectations, as the essence of investment is capturing expectation differences [7][8] - WuXi AppTec's profit forecast for 2025 indicates a significant growth of 41.33% year-on-year, reflecting its foundational role in the global pharmaceutical supply chain and a potential recovery in valuation due to increased R&D investments [7][8] - The vaccine sector is also poised for recovery, with domestic companies expected to benefit from a broad replacement market and initial overseas expansion, indicating a favorable investment outlook [7][8]

Group 1 - The core viewpoint of the news highlights the strong performance of the innovative drug ETF Tianhong (517380) and the medical device ETF (159873), both reaching new highs in terms of scale and shares [1][2] - As of January 13, the innovative drug ETF Tianhong (517380) has a scale of 1.807 billion yuan and 2.162 billion shares, marking a record high since its inception [1] - The innovative drug ETF has seen a net inflow of 264 million yuan over the past six days, indicating strong investor interest [1] Group 2 - The medical device ETF (159873) also reached new highs in scale and shares as of January 13, with a net inflow of 26.503 million yuan over the past four days, leading its category with a net flow rate of 28.22% [2] - The medical device ETF has a high concentration in brain-computer interface stocks, accounting for over 19%, and is expected to benefit from domestic innovation, accelerated exports, and new technologies [2] - WuXi AppTec's stock price reached a new high, with a projected revenue of 45.456 billion yuan for 2025, reflecting a year-on-year growth of 15.84% [3][4] Group 3 - WuXi AppTec's adjusted net profit is expected to be 14.957 billion yuan for 2025, a year-on-year increase of 41.33%, driven by its focus on a unique "integrated, end-to-end" CRDMO business model [3] - The company is expected to maintain strong performance in 2026, supported by a solid business foundation and a clear strategic path [4] - The biopharmaceutical industry is anticipated to face external uncertainties, but WuXi AppTec's comprehensive service capabilities and enhanced quality systems are seen as valuable certainties in the market [4]

Core Insights - The PD-1/VEGF dual antibody sector is experiencing a divergence, with Yiming Oncology's PD-L1/VEGF dual antibody facing a setback due to the return of collaboration by Axion, while Rongchang Biopharma secured a $5.6 billion licensing deal with AbbVie, highlighting the increasing differentiation within the dual antibody space and outlining the core investment theme for 2026—certainty [2][3] Group 1: Investment Trends - The 2025 trend of "BD is king" in China's pharmaceutical investment market has shifted, with a focus on the feasibility of BD transactions rather than blind enthusiasm for total deal amounts [2][4] - The market is moving away from generalized sector speculation towards embracing "certainty" in value, which encompasses three core anchors: expectation certainty, product certainty, and performance certainty [3] Group 2: Expectation Certainty - Expectation certainty emphasizes the need to rationally assess the feasibility of BD transactions rather than blindly pursuing total deal amounts, as the probability of new drugs progressing from early clinical stages to market approval is only 7.9% [4][5] - In the competitive PD-1/VEGF dual antibody sector, companies like Kangfang Biopharma, Sanofi, and Rongchang Biopharma have secured overseas licensing deals worth $5 billion, $6.05 billion, and $5.6 billion respectively, but the overlapping targets and indications mean not all players can realize their expected value [4][5] Group 3: Product Certainty - Product certainty focuses on the ability of a drug to achieve substantial sales post-launch, with products that have clear sales growth logic deserving higher valuation premiums [6] - WanTai Biopharma's nine-valent HPV vaccine, priced at 499 yuan per dose (40% of imported vaccines), is expected to penetrate lower-tier markets and drive sales growth starting in 2026 [6] - In contrast, Innovent Biologics' Ma Shidu peptide faces challenges in commercial viability due to increased competition and pricing pressures, leading to a significant reduction in its sales peak expectations [6] Group 4: Performance Certainty - Performance certainty involves identifying companies and sectors with clear growth or recovery expectations, as the essence of investment is capturing expectation differences [7][8] - WuXi AppTec's profit forecast of 14.957 billion yuan for 2025, a 41.33% increase year-on-year, exemplifies performance certainty and reflects the company's foundational role in the global pharmaceutical supply chain [8] - The vaccine sector, having reached a bottom after previous adjustments, shows potential for growth as domestic companies expand into underdeveloped markets, with increasing performance certainty and investment opportunities [8] Conclusion - The transition from "selling BD expectations" to "realizing certainty" marks a significant shift in pharmaceutical investment strategies for 2026 [9]